Novan, Inc. is a clinical development-stage biotechnology company. The Company is focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases. The Company has created a Nitricil technology platform enabling the development of new chemical entities (NCEs) with delivery of nitric oxide. The Company’s two key components of its nitric oxide platform are its Nitricil technology, which drives the creation of NCEs, and its formulation science, both of which it uses to tune its product candidates for specific indications. Novan’s Nitricil technology enables it to store large amounts of nitric oxide gas in a stable, solid form by chemically loading it on a macromolecule, or polymer. The nitric oxide platform has produced a portfolio that includes the various clinical stage dermatology product candidates: SB204, SB206, SB208 and SB414.